2023

• Tyligand Bioscience Announces First Patient Dosed for the Phase 1 Trial of TSN222，the Global First Dual Action Tumor Immune Agonist
• Tyligand Bioscience Receives Clinical Trial Clearance from U.S. FDA and China NMPA for Dual Function Immune Agonist TSN222